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Septic shock is a severe inﬂammatory state caused by an infectious agent. Our purpose was to investigate serum amyloid A (SAA)
protein and C-reactive protein (CRP) as inﬂammatory markers of septic shock patients. Here we evaluate 29 patients in post-
operative period, with septic shock, in a prospective study developed in a surgical intensive care unit. All eligible patients were
monitored over a 7-day period by sequential organ failure assessment (SOFA) score, daily CRP, SAA, and lactate measurements.
CRP and SAA strongly correlated up to the ﬁfth day of observation but were not good predictors of mortality in septic shock.
Copyright © 2008 Domingos Dias Cicarelli et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Severe sepsis and septic shocks are a common cause of mor-
tality in intensive care unit (ICU) [1]. They are a state of sys-
temic inﬂammation in response to infectious agents that can
lead to multiple organ system failure and death.
The systemic inﬂammatory response to infection in-
volves the release of several mediators, which has led to
the suggestion that some of these mediators could be used
as markers of sepsis severity [2]. Among the acute-phase
proteins that participate in the inﬂammatory response, C-
reactive protein (CRP) is a component of the innate immune
system that binds phosphocoline and recognizes some for-
eign pathogens as well as phospholipid constituents of dam-
age cells; serum amyloid A (SAA) protein is an apolipopro-
tein that rapidly binds to high-density lipoprotein after
their synthesis, inﬂuencing cholesterol metabolism during
inﬂammatory states, causing adhesion and chemotaxis of
phagocitic cells and lymphocytes [3, 4]. In some patients
with chronic inﬂammation, the net eﬀect of increased SAA
production may be deleterious due to tissue deposition of
its fragments and the development of systemic amyloidosis
[3, 5].
CRP and SAA display a similar pattern in most inﬂam-
matory diseases, reaching a maximum serum concentration
about 24 hours after the inﬂammatory process sets in and
slowly decreasing [6]. CRP is commonly used as a marker
of an acute inﬂammatory state, produced by the liver in re-
sponse to tissue injury or infection [7]. Its plasma concentra-
tion has been reported to parallel the clinical course of infec-
tion and the fall of the protein level indicates the resolution
of infection [1]. SAA is the other major acute-phase protein
in humans, with the earliest and highest increase rate of all
acute-phase proteins, including CRP [4, 8]. SAA concentra-
tions usually parallel those of CRP. Some authors have been
reported that SAA appears to be a clinically useful marker
of inﬂammation in bacterial or viral infection likewise CRP
[9]. Although some studies suggest that SAA is a more sensi-
tive marker of inﬂammatory disease, assays for SAA are not
widely available at present [4].
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plasma concentrations in postoperative patients with septic
shock, or has correlated them to the severity of patients rep-
resented by SOFA score. This study aimed to evaluate CRP
andSAAmeasurementsasmarkersofseverityofsepticshock
patients during postoperative period.
2. METHODS
This study was prospective at a surgical ICU. After approval
by a local ethics committee, informed consent was obtained
from patients or from their next of kin prior to enrollment2 Mediators of Inﬂammation
Table 1: Baseline characteristics of the patients.
Characteristics n = 29
Age (years) 65 ± 13.9
Male sex 45%
Weight (kg) 63.5 ±11.7
APACHE II score 19.8 ±4.5
SOFA score 9.6 ±2.3
Prior orpreexistingconditions (%)
Hypertension 31
Myocardial infarction 13.7
Diabetes 13.7
Liver disease 6.9
COPD 6.9
Cancer 20.7
Surgery (%)
Multiple trauma (excluding head trauma) 3.4
Gastrointestinal surgery 75.9
Major vascular surgery 6.9
Thoracic surgery 3.4
Urologic surgery 10.4
Other indicatorsofdiseaseseverity (days)
Mechanical ventilation 4.0 ±3.2
Shock (use of vasopressor) 4.2 ±1.9
APACHE: acute physiology and chronic health evaluation, SOFA: sequential
organ failure assessment, COPD: chronic obstructive pulmonary disease.
[10]. Twenty-nine patients admitted into the surgical ICU
of the Hospital das Cl´ ınicas da Faculdade de Medicina da
Universidade de S˜ ao Paulo had taken part in the study. Ad-
ditional three patients were excluded after their next of kin
gave up the signed consent. Patients with septic shock diag-
nosed during ICU stay were eligible for the study. We used
the American College of Chest Physicians/Society of Criti-
cal Care Medicine Consensus Conference deﬁnition of sepsis
and septic shock [11]. Patients under 18 were excluded.
Severity of illness at the baseline was assessed based
on the acute physiology and chronic health evaluation II
(APACHE II) score [12]. Patients were assessed daily for 7
consecutive days using the sequential organ failure assessment
score (SOFA) or until their discharge from the ICU when oc-
curring in less than 7 days [13–15]. C-reactive protein and
serum amyloid A protein were also measured daily.
The patients received conventional therapy regarding an-
tibiotic regimens, serial blood cultures (whenever that body
temperature >38◦C), and discharge criteria. Relevant clini-
cal and laboratory tests were conducted daily throughout the
study.
BloodsamplesforCRPandSAAdosagewerethawedand
assayed in batches in an automated analyzer (Behring Neph-
elometer Analyzer II, Dade Behring, Marburg, Denmark)
forparticle-enhancedimmunonephelometryusingcommer-
cial kits. The analytical sensitivity and accuracy for CRP was
0.0175mg/L (coeﬃcient of variation (CV) 7,6%). The ana-
lytical sensitivity and accuracy for SAA was determined by
the lower limit of the reference curve and thus depended on
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Figure 1: CRP evolution of survivors and nonsurvivors during the
ﬁrst week (NS). NS: not statistically signiﬁcant.
the concentration of the protein in SAA standard test (CV
between 5.4% and 6.4%).
Statistical analysis was performed using commercial
available package. Multiple logistic regressions were per-
formed to test mortality of 7 or 28 days follow-up. A dis-
tribution analysis was made by the Kolmogorov-Smirnov
test, Pearson correlation coeﬃcients were determined, and
repeated measures were tested by ANOVA. A P value < .05
was considered signiﬁcant.
3. RESULTS
The mean (±SD) age of the 29 patients was 65 ± 13.9 years
( r a n g e ,3 4t o8 8y e a r s ) .T h es t u d yi n v o l v e d1 3m a l e sa n d1 6
females (45%/55%). The APACHE II score of these patients
was 19.8 ± 4.5( Table 1). Table 2 represents the microbiolog-
ical characteristics of the studied patients.
SOFA did not show increase from Day 0 to Day 7 of
observation (P = .589, ANOVA) while CRP reduced signif-
icantly from Day 0 till the end of observation period (P <
.001, ANOVA followed by Holm-Sidak test) as well as SAA
(P < .001, ANOVA followed by Holm-Sidak test) (Table 3).
CRP and SAA concentrations did not present any corre-
lation with SOFA.
On the other hand, CRP and SAA have shown a good
correlation from Day 0 till Day 5 (Table 4).
Mortality of these patients in 7 days was 44.8% (13 in 29)
and in 28 days was 65.5% (19 in 29). CRP and SAA concen-
trations were not associated with Day 7 mortality (Table 5).
CRP and SAA concentrations evolution during the ﬁrst
week comparing survivors and nonsurvivors were not statis-
tically signiﬁcant (Figures 1 and 2).
4. DISCUSSION
The present study revealed signiﬁcant positive correlation
betweenSAAandCRPinpostoperativesepticshockpatients.
SOFAorAPACHEIIdidnotcorrelatewiththoseserummea-
surements. Neither marker nor index was associated with
mortality rate.Domingos Dias Cicarelli et al. 3
Table 2: Microbiological characteristics of patients.
Patient Surgery/phatology Antibiotics Type of organism Type of culture
1 Cholecistectomy/biliary abscess Vanco + cefepime S. aureus Abscess culture
2 Empyema pleural drainage Ceftriaxone + clindamycin S. pyogenes Pleural abscess culture
3 Cholecistectomy/biliary abscess Ceftriaxone + metronidazole — Negative cultures
4 Cystectomy/pyuria Ceftriaxone + metronidazole — Negative cultures
5 Aortic bypass/leg amputation Ceftazidime + clindamycin P. aeruginosa Surgical site culture
6 Colectomy/cavity contamination Ceftriaxone + metronidazole — Negative cultures
7 Calcaneal exposure fracture Ciproﬂoxacin E. faecalis Surgical site culture
8 Pyonephrosis drainage Ceftriaxone K. pneumoniae Urinary culture
9 Sigmoidectomy Ceftriaxone + metronidazole A. baumanii Blood culture
10 Hemicolectomy Ceftriaxone + metronidazole Candida albicans Blood culture
11 Enterectomy/mesenteric ischemia Ceftriaxone + metronidazole — Negative cultures
12 Pancreatic-duodenal resection Ceftriaxone Serratia marcesens BAL
13 Pancreatic-duodenal resection Ceftriaxone + metronidazole S. coag negative Blood culture
14 Retroperitoneal abscess drainage Cefepime + vanco + imipenem P. aeruginosa Blood culture
15 Abdominal aneurysm repair Vanco + imipenem S. aureus Blood culture
16 Sigmoidectomy/perforative lesion Ceftriaxone + metronidazole Serratia marcesens Ascite culture
17 Colectomy Cefepime + vanco S. aureus Blood culture
18 Gastric ulcer Ceftriaxone + metronidazole — Negative cultures
19 Cholecistectomy Cipro + metronidazole Escherichia coli Urinary culture
20 Hemicolectomy Cefepime + vanco + metro E. cloacae Blood culture
21 Enterectomy/cavity contamination Vanco + imipenem — Negative cultures
22 Colectomy Ceftriaxone + metronidazole A. baumanii Blood culture
23 Colectomy Ceftriaxone + metronidazole P. aeruginosa Blood culture
24 Enterectomy/cavity contamination Ceftriaxone + metronidazole — Negative cultures
25 Cervical abscess drainage Imipenem + vanco + metro K. pneumoniae Blood culture
26 Sigmoidectomy/perforative lesion Ceftriaxone + metronidazole P. aeruginosa Blood culture
27 Sigmoidectomy Cefepime + metronidazole S. aureus Blood culture
28 Pyonephrosis drainage Cefepime + metronidazole — Negative cultures
29 Colectomy Ceftriaxone + metronidazole P. aeruginosa BAL
Vanco: vancomycin, Cipro: ciproﬂoxacin, Metro: metronidazole, S. aureus: Staphylococcus aureus, S. pyogenes: Streptococcus pyogenes, P. aeruginosa: Pseu-
domonasaeruginosa,E.faecalis:Enterobacterfaecalis,K.pneumoniae:Klebsiellapneumoniae,A.baumanii:Acinetobacterbaumanii,S.coagnegative:Staphy-
lococcus coagulase negative, E. cloacae: Enterobacter cloacae, BAL: bronchoalveolar lavage.
Table 3: SOFA, CRP, and SAA during the study period (mean ± SD).
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
SOFA 9.6 ±2.31 0 ±2.69 .4 ±4.19 .8 ±4.49 .4 ±4.29 .9 ±3.78 .7 ±4.18 .6 ±3.5
CRP 19.8 ±8.42 0 .9 ±9.11 6 .3 ±6.21 3 .2 ±5.91 1 .8 ±7.71 2 .7 ±11.21 1 .9 ±8.31 0 .0 ±4.4
SAA 47 ±39.83 7 .2 ±28.12 9 ±21.48 22.7 ±18.41 8 .6 ±20.82 4 .7 ±25.82 2 .2 ±20.52 1 .7 ±16.8
SOFA: sequential organ failure assessment, CRP: C-reactive protein, SAA: serum amyloid A. ANOVA. Equal variance test: SOFA P = .956, CRP P = .062, SAA
P = .055.
SAA has been considered by some authors to be equiva-
lent to CRP in patients with bacterial infectious diseases in
clinical practice [16]. Other authors suggest that SAA is a
more sensitive marker than CRP in infections with low in-
ﬂammatory activity (including many viral infections) and in
other clinical conditions, especially those involving the lung
tissue [16, 17]. Yet other studies have conﬁrmed the role of
SAA and CRP in diagnosis and management of neonatal in-
fections [2, 18].
The patterns of cytokine production and the acute-phase
responsediﬀer for diﬀerentinﬂammatoryconditions. Acute-
phasechangesreﬂectthepresenceandintensityofinﬂamma-
tion and they have long been used as a clinical guide for di-
agnosis and management. Among patients with plasma CRP
concentrations higher than 10mg/dL, 80-to-85 percent have
bacterial infections [4, 19]. In our study, all the patients were
insepticshockwithdocumentedinfection.Wecouldobserve
that all patients during the 7-day period of observation pre-
sented plasma CRP concentrations greater than 10mg/dL,
according to results that Gabay et al. in a review article cited
[4]. This fact could indicate that sepsis is secondary to bac-
terial infections. In relation to plasma SAA concentrations, a4 Mediators of Inﬂammation
Table 4: Pearson coeﬃcient for SAA and CPR.
rP -value
Day 0 0.682 .0001
Day 1 0.660 .0004
Day 2 0.464 .034
Day 3 0.529 .024
Day 4 0.651 .0062
Day 5 0.778 .0028
Day 6 0.578 .628
Day 7 0.081 .822
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Figure 2: SAA evolution of survivors and nonsurvivors during the
ﬁrst week (NS). NS: not statistically signiﬁcant.
Table 5: Maximum likelihood, Wald statistic (P-value).
APACHE II SOFA CPR SAA
Day 0 3.46 (.06) 2.46 (.11) 0.02 (.89) 1.91 (.17)
Day 1 3.06 (.08) 3.50 (.06) 1.01 (.31) 0.03 (.86)
Day 3 0.00 (.98) 0.00 (.98) 0.00 (.98) 0.00 (.98)
cutoﬀ value has not been determined from previous studies.
We observed a level higher or closer to 20mg/dL, but more
studies were needed to ﬁnd a cutoﬀ v a l u ef o rS A Aa sa ne a r l y
diagnostic tool for patients with infection.
We did not observe diﬀerence between CRP and SAA
early (Day 1) concentrations in patients who survived com-
pared with those who died. Other authors have found that
these proteins were not prognostic markers in patients with
septic shock [7, 19]. This fact is in concordance with our re-
sults.
PreviousreportshaveobservedthatCRPlevelwasassoci-
ated with organ failure in critically ill patients, although not
speciﬁcallyundersepticshock[14].Thisstudycouldnotﬁnd
any good correlation between CRP or SAA with SOFA, prob-
ably not in agreement with other authors [20]. They believe
that both CRP and SAA are good markers of organ dysfunc-
tion, considering the established diagnostic of septic shock.
Study limitations are attributed primarily to the small
sample size and the age of the patients that could inﬂuence
CRP levels. Some authors believe that the older the patient
is, the higher CRP levels that can be observed [21].
In conclusion, SAA protein and CRP are strongly corre-
lated, but were not good predictors of organ dysfunction and
mortality in septic shock.
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